Trigyn Technologies Shareholders Approve Director Re-appointments and Consultancy Renewal
Trigyn Technologies' shareholders approved key resolutions via postal ballot. Dr. Raja Mohan Rao Potluri's directorship continues, and Ms. Lakshmi Potluri is re-appointed as Independent Director for a five-year term from August 11, 2026. The consultancy agreement with Mr. R. Ganapathi is renewed for one year from February 20, 2026, at ₹12 Lakhs per annum.
The re-appointment of directors and renewal of consultancy services are important for business continuity and governance but do not represent a significant immediate financial impact or strategic shift for the company.
The company received overwhelming approval from its shareholders for all proposed resolutions, including director re-appointments and a consultancy agreement renewal, indicating strong shareholder confidence.
Trigyn Technologies Limited announced the results of its postal ballot and the scrutinizer's report, indicating that all resolutions put forth to the members have been duly approved with the requisite majority.
The resolutions included the continuation of Dr. Raja Mohan Rao Potluri's directorship as a Non-Executive, Non-Independent Director (Promoter Category) upon attaining the age of 75 years, effective July 15, 2026. This was approved by 99.865% of the votes cast in favor.
Additionally, Ms. Lakshmi Potluri was re-appointed as an Independent Director for a second term of five years, commencing August 11, 2026, up to August 10, 2031. This resolution received 99.644% approval.
The company also secured approval for the continuation and renewal of the Consultancy Services Agreement with Mr. R. Ganapathi, a Non-Executive Director, for a further period of one year commencing February 20, 2026, up to February 19, 2027, at an annual consultancy fee of ₹12,00,000. This ordinary resolution was passed with 99.643% in favor.
The postal ballot process, including remote e-voting, was conducted from May 26, 2026, to June 24, 2026. The scrutinizer's report, dated June 24, 2026, confirmed the approval of all resolutions.
What to do with a filing like this
Trigyn Technologies Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Trigyn Technologies Limited. Read the original for the full detail.